Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Here’s a closer look at the top pharmaceutical companies that have earned favorable rankings from Wolfe Research analysts. Johnson & Johnson takes the top spot with growth primarily driven by new ...

Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

See related editorial at Key points In 2002, the G8 summit in Kananaskis, Alberta, launched the G8 Africa Action Plan,[1][2] which identified HIV/AIDS as a central threat to human development and ...

By shutting South Africa out of its overseas funding for the roll-out of the revolutionary six-monthly HIV prevention jab ...

Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

If injectable medication to prevent infection, which has gained favour across Canada, were widely available in B.C., it would ...

Gilead Foundation announced a commitment of more than $3 million in new grants to help address critical gaps in education, care delivery and support services for people affected by metastatic breast ...